183 related articles for article (PubMed ID: 9884823)
1. Value of Ki67 immunostain in identification of malignancy in serous effusions.
Saleh H; Bober P; Tabaczka P
Diagn Cytopathol; 1999 Jan; 20(1):24-8. PubMed ID: 9884823
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions.
Hafez NH; Tahoun NS
J Egypt Natl Canc Inst; 2011 Dec; 23(4):155-62. PubMed ID: 22776843
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of p53 protein in the study of serous effusions.
Zoppi JA; Pellicer EM; Sundblad AS
Acta Cytol; 1995; 39(4):721-4. PubMed ID: 7631546
[TBL] [Abstract][Full Text] [Related]
4. Improved detection of adenocarcinoma of serous fluids with p53 immunocytochemistry.
Saleh HA; Bober P; Tabaczka P
Acta Cytol; 1998; 42(6):1330-5. PubMed ID: 9850638
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
Klech H; Rona G; Hutter C; Bayer PM; Kummer F
Wien Klin Wochenschr; 1986 Sep; 98(17):564-73. PubMed ID: 3020811
[TBL] [Abstract][Full Text] [Related]
6. Suspicious for Malignancy Diagnoses on Pleural Effusion Cytology.
Rodriguez EF; Pastorello RG; Morris P; Saieg M; Chowsilpa S; Maleki Z
Am J Clin Pathol; 2020 Aug; 154(3):394-402. PubMed ID: 32525969
[TBL] [Abstract][Full Text] [Related]
7. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
8. The role of liquid-based cytology and ancillary techniques in pleural and pericardic effusions: an institutional experience.
Rossi ED; Bizzarro T; Schmitt F; Longatto-Filho A
Cancer Cytopathol; 2015 Apr; 123(4):258-66. PubMed ID: 25641902
[TBL] [Abstract][Full Text] [Related]
9. Cytohistological correlation in serous effusions using the newly proposed International System for Reporting Serous Fluid Cytopathology: Experience of an oncological center.
Lobo C; Costa J; Petronilho S; Monteiro P; Leça L; Schmitt F
Diagn Cytopathol; 2021 May; 49(5):596-605. PubMed ID: 32339444
[TBL] [Abstract][Full Text] [Related]
10. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
11. p53 gene product in pleural effusions. Practical use in distinguishing benign from malignant cells.
Mullick SS; Green LK; Ramzy I; Brown RW; Smith D; Gondo MM; Cagle PT
Acta Cytol; 1996; 40(5):855-60. PubMed ID: 8842156
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the c-Met immunostain to detect malignant cells in body cavity effusions.
Zimmerman RL; Fogt F
Oncol Rep; 2001; 8(6):1347-50. PubMed ID: 11605063
[TBL] [Abstract][Full Text] [Related]
13. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells.
Davidson B; Nielsen S; Christensen J; Asschenfeldt P; Berner A; Risberg B; Johansen P
Am J Surg Pathol; 2001 Nov; 25(11):1405-12. PubMed ID: 11684957
[TBL] [Abstract][Full Text] [Related]
14. The beta subunit of human chorionic gonadotropin lacks specificity for malignant cells in serous effusions.
Zimmerman RL; Fogt F
Mod Pathol; 2004 Jun; 17(6):701-4. PubMed ID: 15001996
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions.
Toumbis M; Rasidakis A; Passalidou E; Kalomenidis J; Alchanatis M; Orphanidou D; Jordanoglou J
Anticancer Res; 1996; 16(4A):2101-4. PubMed ID: 8712750
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of monoclonal antibody B72.3 in detecting adenocarcinoma cells in serous effusions.
Lauritzen AF
APMIS; 1989 Aug; 97(8):761-6. PubMed ID: 2765278
[TBL] [Abstract][Full Text] [Related]
17. Serous effusions in malignant lymphomas: a review.
Das DK
Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Value of the EZH2 Immunomarker in Malignant Effusion Cytology.
Ang PP; Tan GC; Karim N; Wong YP
Acta Cytol; 2020; 64(3):248-255. PubMed ID: 31352449
[TBL] [Abstract][Full Text] [Related]
19. Cytologic diagnosis of malignant mesothelioma in serous effusions using an antimesothelial-cell antibody.
Donna A; Betta PG; Bellingeri D; Tallarida F; Pavesi M; Pastormerlo M
Diagn Cytopathol; 1992; 8(4):361-5. PubMed ID: 1638937
[TBL] [Abstract][Full Text] [Related]
20. [Usefulness of AgNOR technique in the interpretation of serous effusions].
Rocher AE; Blanco AM; Palaoro LA
Rev Med Chil; 2000 Sep; 128(9):963-8. PubMed ID: 11349500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
